pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Descovy
drug
save

(emtricitabine + tenofovir alafenamide)

Marketedupdated 3mo ago
by $GILD GILEAD SCIENCES, INC.
Approved
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying (emtricitabine + tenofovir alafenamide)

  • phase4PrEP at a Syringe Services Programcompletedn=90
  • phase4Telehealth as a Modality to Increase the Uptake of PrEP Services in Black and Latino: "e-PrEP"completedn=75
  • phase3SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorderrecruitingn=40
  • —Express Testing and Same-day Initiation of PrEP Studyunknownn=816

Patent cliff

source: FDA Orange Book
first barrier falls
Jun 20, 2028
~1.9 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (8)

  • Feb 15, 2033patentUS 8754065*PED
  • Feb 15, 2033patentUS 8754065*PED
  • Feb 15, 2033patentUS 9296769*PED
  • Feb 15, 2033patentUS 9296769*PED
  • Aug 15, 2032compositionUS 8754065
  • Aug 15, 2032compositionUS 8754065
  • Aug 15, 2032compositionUS 9296769
  • Aug 15, 2032compositionUS 9296769

FDA exclusivities (3)

  • Jan 7, 2029ODE-457Orphan Drug (7y)2.4y
  • Jun 20, 2028M-316Method (3y)1.9y
  • Jun 20, 2028M-316Method (3y)1.9y

News(4)

  • Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
    Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.
    biopharma_dive · 6d ago
  • Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts
    HIV remained Gilead’s strongest franchise in the second quarter, but the pharma is building out its pipeline beyond virology, particularly focusing on inflammation and oncology.
    biospace · 6d ago
  • STAT+: AIDS activists slam Biden R&D deal with Gilead over HIV prevention drug patents
    A group of AIDS activists obtained an R&D pact at the heart of a settlement between the U.S. government and Gilead Sciences over patents for HIV prevention.
    stat · 29d ago
  • STAT+: AIDS group sues Trump administration over undisclosed agreement with Gilead
    The AIDS advocacy group PrEP4All has sued the Trump administration over an undisclosed agreement with Gilead.
    stat · 3mo ago
brand
Descovy
generic
(emtricitabine + tenofovir alafenamide)
indication
Human Immunodeficiency Virus (HIV) Infections (AIDS)
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?